← All Harmony Biosciences Holdings, INC filings

Harmony Biosciences Holdings, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
HRMY
Harmony Biosciences Holdings, INC
10-K: Harmony Biosciences: WAKIX Drives Growth, Pipeline Expands
Harmony Biosciences reports strong 2025 revenue growth for WAKIX, expands its neuroscience pipeline, and navigates generic competition.
NASDAQ
HRMY
Harmony Biosciences Holdings, INC
10-K: Harmony Biosciences Holdings Reports Strong 2024 Results, Navigates Regulatory Hurdles
Harmony Biosciences Holdings, Inc. announces its 2024 financial results, highlighting growth in WAKIX sales while addressing regulatory challenges and pipeline expansion.
NASDAQ
HRMY
Harmony Biosciences Holdings, INC
10-K/A: Harmony Biosciences Amends 10-K Filing to Disclose Officer Trading Plans
Harmony Biosciences has filed an amendment to its annual report to include details of Rule 10b5-1 trading arrangements by its officers.
NASDAQ
HRMY
Harmony Biosciences Holdings, INC
10-K: Harmony Biosciences Reports 2023 Financial Results, Advances Pipeline
Harmony Biosciences Holdings, Inc. released its 2023 annual report, highlighting financial performance and progress in its clinical development programs.